Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Datametrex AI Ltd V.DM

Alternate Symbol(s):  DTMXF

Datametrex AI Limited is a technology-focused company with exposure to artificial intelligence, healthcare, and mobile gaming. It is focused on collecting, analyzing and presenting structured and unstructured data using machine learning and artificial intelligence. The Company's products include AnalyticsGPT, Cyber Security, and Healthcare. AnalyticsGPT platform scans vast data streams from social media, news, blogs, forums, messengers, enterprise data, and the dark Web, creating predictive analytics. Cyber Security is a deep analytics platform that captures, structures, and visualizes vast amounts of unstructured social media data, which is used as a discovery tool that allows organizations to make decisions. It offers Nexa Products, which consists of NexaSecurity and NexaSMART. Healthcare consists of Imagine Health Centres, a multidisciplinary healthcare facility, and Medi-Call, a telehealth platform. The Company also offers a mobile blockchain game, Cereal Crunch.


TSXV:DM - Post by User

Post by Thecook100on Jan 04, 2023 8:48am
137 Views
Post# 35202267

Excellent News. One step closer to major exposure :)

Excellent News. One step closer to major exposure :)

oronto, Ontario--(Newsfile Corp. - January 4, 2023) - Datametrex AI Limited (TSXV : DM) (FSE : D4G) (OTCQB : DTMXF) (the "Company" or "Datametrex") is pleased to announce that Medi-Call Inc. ("Medi-Call"), the Company's wholly-owned telehealth company, has signed a partnership agreement with Lucira Health ("Lucira"), signed December 22, 2022, for providing Medi-Call's telehealth services to Lucira clients.

Lucira has created a Health Canada-approved at-home diagnostic testing device for detecting both COVID-19 and the flu, influenza A and B. Lucira will direct patients to Medi-Call's telehealth services through the Lucira app and website, which exposes Medi-Call to more potential patients. Lucira has combined the most accurate COVID-19 test with the only commercially available at-home flu test. Within 30 minutes or less, users will know whether they have COVID-19 or the flu. Once results are in, if Lucira users are positive for any viruses, their platform will redirect users to Medi-Call's telehealth services to see a physician or get a prescription. Lucira's diagnostic testing has been chosen by some of the most notable organizations in Canada such as Netflix, Air Canada, Amazon, and Sony Pictures. (Source: https://www.lucirahealth.com/). This gives Medi-Call the opportunity to expand its services to a broader range of new potential clients.

With COVID-19 and flu symptoms being vastly similar, knowing which infection you have can be challenging. Lucira's molecular, nucleic acid amplification test (NAAT) provides accurate, at-home test results. Though Lucira is a self-test, it has more advanced technology than a rapid antigen test. The self-tests have analytical sensitivity, allowing the testing technology to detect viruses that have accuracy rates of 98%-99% in detection results, compared to lab-based PCR (Polymerase Chain Reaction) tests. This means Lucira's at-home testing is just as accurate as PCR testing.

(Source: https://www.lucirahealth.ca/science/)

Additionally, several studies were conducted by Lucira to ensure the legitimacy and accuracy of their at-home testing. Accuracy rates range from 98%-99% during these trials. The below chart summarizes Lucira's findings:

Cannot view this image? Visit: https://images.newsfilecorp.com/files/1778/150223_c9248d6614bc4957_002b.jpg

Figure 1

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/1778/150223_c9248d6614bc4957_002bfull.jpg

To learn more about Lucira's clinical studies, please visit: https://www.lucirahealth.com/science/

"We are one step closer to providing accessible healthcare to all Canadians. Lucira has fantastic technology that allows users to determine their COVID-19 or flu status at home, with PCR results. Being represented on the Lucira platform increases Medi-Call's exposure to more potential patients and business. This new year, the Company is focused on growing our healthcare intiatives and expanding business," said Marshall Gunter, CEO of the Company.

<< Previous
Bullboard Posts
Next >>